Sept. 24, 2007 - Progen Pharmaceuticals Limited (ASX: PGL; Nasdaq: PGLA) : the Phase 2 trial administering 250mg of PI-88 in combination with the chemotherapeutic agent docetaxel to patients with advanced non small cell lung cancer did not meet its primary endpoint of significantly improving the progression-free rate at six months compared to docetaxel alone. The trial also did not meet its secondary endpoints of improvement in time to progression, response rate, overall survival and quality of life measures... Progen's Press release [PDF] -
Showing posts with label Progen. Show all posts
Showing posts with label Progen. Show all posts
Sep 25, 2007
Progen , PI-88 Phase 2 Lung Cancer Results
Sept. 24, 2007 - Progen Pharmaceuticals Limited (ASX: PGL; Nasdaq: PGLA) : the Phase 2 trial administering 250mg of PI-88 in combination with the chemotherapeutic agent docetaxel to patients with advanced non small cell lung cancer did not meet its primary endpoint of significantly improving the progression-free rate at six months compared to docetaxel alone. The trial also did not meet its secondary endpoints of improvement in time to progression, response rate, overall survival and quality of life measures... Progen's Press release [PDF] -
Subscribe to:
Posts (Atom)
